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Abstract
Background: The extrinsic apoptotic pathway initiates when a death ligand, such as the Fas ligand, interacts with
its cell surface receptor (ie., Fas/CD95), forming a death-inducing signaling complex (DISC). The Fas-dependent
apoptotic pathway has been implicated in several models of lung or vascular injury. Carbon monoxide, an
enzymatic product of heme oxygenase-1, exerts antiapoptotic effects at low concentration in vitro and in vivo.
Methods: Using mouse lung endothelial cells (MLEC), we examined the antiapoptotic potential of carbon
monoxide against apoptosis induced by the Fas/CD95-activating antibody (Jo2). Carbon monoxide was applied to
cell cultures in vitro. The expression and/or activation of apoptosis-related proteins and signaling intermediates
were determined using Western Immunoblot and co-immunoprecipitation assays. Cell death was monitored by
lactate dehydrogenase (LDH) release assays. Statistical significance was determined by student T-test and a value of
P < 0.05 was considered significant.
Results: Treatment of MLEC with Fas-activating antibody (Jo2) induced cell death associated with the formation of
the DISC, and activation of caspases (-8, -9, and -3), as well as the pro-apoptotic Bcl-2 family protein Bax. Exposure
of MLEC to carbon monoxide inhibited Jo2-induced cell death, which correlated with the inhibition of DISC
formation, cleavage of caspases-8, -9, and -3, and Bax activation. Carbon monoxide inhibited the phosphorylation
of the Fas-associated death domain-containing protein, as well as its association with the DISC. Furthermore,
carbon monoxide induced the expression of the antiapoptotic protein FLIP and increased its association with the
DISC.
CO-dependent cytoprotection against Fas mediated apoptosis in MLEC depended in part on activation of ERK1/2-
dependent signaling.
Conclusions: Carbon monoxide has been proposed as a potential therapy for lung and other diseases based in
part on its antiapoptotic effects in endothelial cells. In vitro, carbon monoxide may inhibit both Fas/caspase-8 and
Bax-dependent apoptotic signaling pathways induced by Fas-activating antibody in endothelial cells. Strategies to
block Fas-dependent apoptotic pathways may be useful in development of therapies for lung or vascular disorders.
Background
Apoptosis, a form of programmed cell death, serves a
critical function in the maintenance of tissue homeosta-
sis under physiological conditions, as a component of
developmental programs. Dysregulation of apoptosis
may contribute to the progression of a number of dis-
ease states, including cancer, autoimmunity, and neuro-
degenerative disorders [1,2]. Furthermore, apoptosis has
also been implicated in the pathogenesis of several
pulmonary diseases, including acute lung injury/acute
respiratory distress syndrome (ALI/ARDS) [3,4], and
chronic obstructive pulmonary disease [5].
Apoptosis requires the regulated activation of pro-
teases (ie., caspases) and nucleases within an intact cell
membrane. Two apoptotic pathways have been identi-
fied by which cells can initiate and execute the cell
death process: an intrinsic (mitochondria-dependent)
pathway and an extrinsic (death receptor-dependent)
pathway [6-8]. Intrinsic apoptosis involves the activation
and mitochondrial translocation of pro-apoptotic Bcl-2
family members (e.g., Bax), leading to mitochondrial
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cytochrome-c).
Extrinsic apoptosis initiates with the plasma mem-
brane assimilation of the death-inducing signaling
complex (DISC), consisting of Fas, FADD, and caspase-
8, by ligand-dependent (ie., Fas ligand, FasL) or inde-
pendent mechanisms. Death receptors, a subset of type
I transmembrane receptors of the tumor necrosis fac-
tor receptor family/nerve growth factor receptor family
directly transduce apoptotic signals. Among these, Fas
(Apo-1/CD95), is a transmembrane cell surface recep-
tor containing three cysteine-rich extracellular domains
at the amino-terminus, which are responsible for ligand
binding, and an intracytoplasmic death domain (DD) of
~80 amino acids essential for transducing the apoptotic
signal [9]. Binding of FasL to Fas causes a higher-order
aggregation of the receptor molecules and recruitment
of the adaptor molecule Fas-associated death domain
(FADD) via DD-DD interactions. FADD also contains a
death effector domain, which recruits pro-caspase-8
(FLICE) and/or pro-caspase-10 to the receptor. The
resulting multimeric protein complex forms within sec-
onds of receptor engagement [10]. Autoproteolytic
activation of caspase-8 results in the processing of Bid
to tBid, which assimilates into the mitochondria to
trigger cytochrome c release, and may facilitate Bax
activation [11].
FLIP, also known as Fas-associated death domain
(FADD) interleukin-1b-converting enzyme (FLICE)-like
inhibitory protein has been characterized as an inhibitor
of apoptosis induced by death receptors such as Fas.
Multiple splice variants of c-FLIP have been found. Of
these, three could be detected at the protein level. These
are designated as c-FLIP short (c-FLIPS), c-FLIP long (c-
FLIPL), and c-FLIP Raji (c-FLIPR) [12-16]. While all
these isoforms of FLIP interfere with caspase-8 cleavage,
only FLIPL is cleaved at the DISC, whereas FLIPS and
FLIPR inhibit caspase-8 by remaining in the DISC.
Increased levels of FLIPL can confer protection against
Fas-induced apoptosis [12-16].
We previously reported that the expression of FLIP
protected against cell death in pulmonary epithelial and
endothelial cells subjected to hyperoxia [17,18], or in
endothelial cells subjected to hypoxia/reoxygenation
[19].
Carbon monoxide (CO) occurs in nature as a product
of the combustion of organic materials. CO also arises
endogenously in cells and tissues as a product of heme
oxygenase (HO) activity, which degrades heme to bili-
verdin-IXa and ferrous iron [20]. HO-1, the inducible
form of HO, responds to transcriptional upregulation by
multiple forms of cellular stress. HO-1 confers cytopro-
tection against oxidative stress in vitro and in vivo [21].
HO-derived CO acts as a vasorelaxant and inhibits
other vascular functions such as platelet aggregation and
smooth muscle proliferation [22]. When applied at low
concentration, CO exerts potent cytoprotective effects
mimicking those of HO-1 induction, which include anti-
inflammatory effects in macrophages [23,24], as well as
antiapoptotic effects in vascular cells [25,26]. HO-1 and/
or CO provide tissue protection in a number of in vivo
models, including vascular injury, ischemia/reperfusion
(I/R) injury, oxidative lung injury [27-32], and organ
transplantation [33]. The mechanisms of CO action
potentially involve modulation of intracellular signaling
pathways, including activation of p38 MAPK, and solu-
ble guanylyl cyclase [23,34,35].
Exposure to low concentrations of CO prevents the
initiation of apoptosis in various cultured cells
[25,36,37]. Using mouse lung endothelial cells (MLEC),
we have previously demonstrated that CO treatment
inhibited apoptosis in a model of hyperoxia-induced oxi-
dative stress [37]. In the current study, we demonstrate
that CO prevented Fas-activating antibody (Jo2)-induced
apoptosis in MLEC by inhibition of both extrinsic and
intrinsic apoptotic pathways.
Methods
Chemical and Reagents
Antibodies: anti-Bax, anti-caspase-8, anti-caspase-9, anti-
caspase-3, anti-Fas, anti-FLIP, and protein A-agarose
were from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Anti-NF-B p65, anti-P44/42, anti-JNK and
anti-FADD were from Cell Signaling Technology, Inc.
(Beverly, MA). Anti-Bax 6A7 antibody was purchased
from BD PharMingen (San Diego, CA). The lactate
dehydrogenase (LDH) assay kit was from Roche Diag-
nostics Corporation (Indianapolis, IN). JNK inhibitor-II
and PD 98059 were from Calbiochem (San Diego, CA).
Digitonin and all other reagent chemicals were from
Sigma (St. Louis, USA).
Isolation and Culture of Murine Lung Endothelial Cells
Endothelial cells were isolated by an immunobead pro-
tocol as previously described [38]. Briefly, mouse lungs
were digested in collagenase and filtered through 100-
μm cell strainers, centrifuged, and washed twice with
medium. Cell suspensions were incubated with a mono-
clonal antibody (rat anti-mouse) against platelet
endothelial cell adhesion molecule-1 for 30 min at 4°C.
The cells were washed twice to remove unbound anti-
body, and resuspended in a binding buffer containing
washed magnetic beads coated with sheep anti-rat
immunoglobulin G. Attached cells were washed four to
five times in culture medium, and then digested with
trypsin/EDTA to detach the beads. Bead-free cells were
centrifuged and resuspended for culture. After two pas-
sages, the cells were incubated with fluorescent-labeled
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absorbed by endothelial cells and macrophages, and
sorted to homogeneity by fluorescence-activated cell
sorting.
Cell Culture and Treatments
The MLEC (passages 4-6) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal
bovine serum, 6.32 g/liter HEPES, and 3.3 ml of
endothelial cell growth supplements in humidified incu-
bators at 37°C. For Fas-activating antibody treatment,
cultures were changed to serum-free medium, to which
200 ng/ml of anti-Fas antibody (Jo2) was added for the
time indicated. PD 98059 from DMSO stock solution
was applied at a final concentration of 25 μMf o r3 0
min prior to Jo2 antibody treatment.
Carbon Monoxide Exposure
Cell cultures were treated in vitro with CO (250 ppm) in
compressed air containing 5% CO2, in a modular expo-
sure chamber as previously described [23]. A CO analy-
zer (Interscan Corp., Chatsworth, CA) was used to
measure CO levels in the chamber. For all experiments
involving exposure to CO, cells were pretreated with
CO for 2 h.
Lactate Dehydrogenase (LDH) Release Assay
LDH release was measured using a commercially avail-
able assay (Cytotoxicity Detection Kit; Roche Molecular
Biochemicals). After gentle agitation, 200 μl of medium
was removed at various times to be used for the assay.
The samples were incubated (30 min) with buffer con-
taining NAD
+, lactate, and tetrazolium. LDH converts
lactate to pyruvate generating NADH. The NADH then
reduces tetrazolium (yellow) to formazan (red), which
was detected by absorbance at 490 nm.
Immunoprecipitation and Western Blot Analysis
Proteins were isolated from MLEC cultures in immuno-
precipitation buffer (1 × PBS, 1% (vol/vol) Nonidet P-40,
0.5% (weight/vol) sodium deoxycholate, 0.1% (weight/
vol) sodium dodecyl sulphate, 0.1 mg/ml phenylmethyl-
sulfonyl fluoride, 30 μl/ml aprotinin, and 1 mM sodium
orthovanadate). For immunoprecipitation, 1 μgo fa n t i -
body (anti-Fas, anti-6A7) was added to 500 μgo ft o t a l
protein in 500 μl, rotated for 2 h at 4 °C, and then incu-
bated with 20 μl of beads (protein A-sucrose, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) for 2 h, spun
down at 500 × g, and washed three times with immuno-
precipitation buffer. Then, 20 μl of loading buffer (100
mM Tris-HCl, 200 mM dithiothreitol, 4% SDS, 0.2%
bromphenol blue, and 20% glycerol) was added. For
SDS-PAGE, samples containing equal amounts of pro-
tein were boiled in the loading buffer and separated on
SDS-PAGE, followed by transfer to polyvinylidene
difluoride membranes. The membranes were blocked
with 5% nonfat milk and stained with the primary anti-
bodies for 2 h at the optimal concentrations. After five
washes in phosphate-buffered saline with 0.2% Tween
20, the horseradish peroxidase-conjugated secondary
antibody was applied, and the blot was developed with
enhanced chemiluminescence reagents (Amersham Bios-
ciences, Piscataway, NJ).
Statistical Analysis
All values are expressed as means +/- SE. Statistical sig-
nificance was determined by student T-test and a value
of P < 0.05 was considered significant.
Results
CO inhibits Fas activating antibody-induced apoptosis
and caspase-9, -3 cleavage
The Fas-signaling pathway initiates upon stimulation
with a specific ligand (Fas ligand) or an activating anti-
Fas antibody, resulting in the activation of downstream
caspases. We investigated the effect of CO on cell death
induced by Fas-activating antibody (Jo2) in MLEC, using
lactate dehydrogenase (LDH) release as a marker. As
shown in Figure 1A, CO protected MLEC from Jo2-
dependent cell death, relative to the air-exposed control.
After 1 h of incubation with the activating anti-Fas anti-
body Jo2, caspase-9 and caspase-3 were cleaved in
MLEC (Figure 1B). Carbon monoxide (CO) exposure
delayed the activation (cleavage) of both caspases in
response to Jo2 (Figure 1B), suggesting that CO inhibits
Fas-dependent apoptosis in endothelial cells.
CO provides protection against extrinsic apoptosis
To investigate the mechanisms involved in the CO-
dependent inhibition of Jo2-induced apoptosis, we tested
the hypothesis that CO inhibits activation of extrinsic
apoptotic signaling pathways. The treatment of MLEC
with Jo2 induced DISC formation (Figure 2A) and acti-
vated caspase-8 (Figure 2B). When MLEC were treated
with Jo2 in the presence of CO (250 ppm), the CO
treatment inhibited Jo2-dependent DISC formation (Fig-
ure 2A) and caspase-8 activation (Figure 2B), relative to
air-treated controls.
CO inhibits Bax activation
We next tested whether an intrinsic apoptosis pathway
involving Bax may participate in apoptogenic signaling
pathways activated by Jo2. The treatment of MLEC with
Jo2 resulted in the activation of Bax (Figure 2C), as
determined by immunoprecipitation with the anti-Bax
monoclonal antibody 6A7, which specifically recognizes
a conformational change in Bax protein associated with
its activation [38]. Bax activation is a hallmark of the
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secondary to extrinsic apoptosis through the caspase-8
dependent activation of Bid [17]. CO decreased Jo2-
inducible Bax activation (Figure 2C) relative to air-trea-
ted controls.
CO upregulates FLIP expression and increases FLIP in the
DISC
We hypothesized that CO may protect MLEC from Jo2-
dependent apoptosis by regulating the expression of
FLIP. In MLEC stimulated with Jo2, CO treatment upre-
gulated FLIPL (Figure 3A), and increased the amount of
FLIP protein associated with the DISC relative to air-
treated controls (Figure 3B). These results suggest that
CO, by upregulating FLIPL and its association with the
DISC, inhibits the recruitment and activation of cas-
pase-8.
CO decreases FADD phosphorylation and its recruitment
in the DISC via inhibition of JNK signaling
Treatment of MLEC with Jo2 increased the time-depen-
dent phosphorylation of FADD (Figure 4A). Further-
more Jo2 treatment time-dependently increased the
phosphorylation of FADD in association with the DISC
in MLEC (Figure 4B), indicating that FADD phosphory-
lation may be necessary for DISC formation in MLEC.
CO (250 ppm) decreased the phosphorylation of FADD
in response to Jo2 stimulation, relative to air-treated
controls (Figure 4A). CO also dramatically decreased
FADD phosphorylation in the DISC (Figure 4B).
In the presence of Jo2, CO exposure (250 ppm) time-
dependently downregulated the phosphorylation of c-
Jun-NH2-terminal kinase (JNK) in MLEC, relative to
that of air-treated controls (Figure 4C). Treatment with
JNK inhibitor-II (JNKi-II), an inhibitor of JNK-1/2
decreased FADD phosphorylation in the DISC (Figure
4D). The data suggest that CO inhibits FADD phos-
phorylation, possibly via inhibition of JNK; and that
JNK-1/2 may be necessary for the phosphorylation of
FADD and/or its recruitment into the DISC induced by
Jo2 antibody.
CO activates ERK1/2 and NFB signaling
Next we tested the effect of CO on NF-Ba n dE R K 1 / 2
activation in Jo2 treated MLEC. Jo2 treatment of MLEC
stimulated the time-dependent phosphorylation of
Figure 1 CO inhibits cell death and caspase activation induced by Fas activating antibody Jo2. MLEC cultures were pretreated in the
absence or presence of CO (250 ppm) for 2 h prior to the addition of antibody Jo2 (200 ng/ml) for the indicated times. 200 μl of supernatant
medium was removed for LDH assays as described in Methods (A). The data represent an average of two independent experiments with each
sample in triplicate (n = 3). Data from Jo2 treated cells in the presence of CO were compared with control (Jo2 treatment alone) cells at each
time point using Student’s T-test (*P < 0.05). The total lysates were subjected to Western blot to detect caspase-9 and caspase-3. b-actin served
as the standard (B). Westerns are representative of three independent experiments.
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treatment (Figure 5). Exposure to CO (250 ppm) further
increased ERK1/2 activation with similar kinetics. Jo2
treatment alone did not appreciably induce NF-Bp 6 5
phosphorylation in cells pretreated with air. On the
other hand, 2 hours pretreatment with CO (250 ppm)
caused a dramatic upregulation of NF-B p65 phosphor-
ylation at the time of Jo2 addition (0 hr), which per-
sisted for 12 hrs (Figure 5).
W en e x tt e s t e dt h er o l eo ft h eE R K 1 / 2M A P Kp a t h -
way in Jo2-mediated cell killing and in the cytoprotec-
tion afforded by CO. MLEC were treated with the
ERK1/2 pathway inhibitor PD 98059, which specifically
targets MEK1, the upstream regulator of ERK1/2. Treat-
ment with PD 98059 sensitized MLEC to Jo2 mediated
cell killing, and partially compromised the ability of CO
to confer protection against Jo2 toxicity, as determined
by LDH release assays (Figure 6A). The requirement for
ERK1/2 pathway in CO-dependent suppression of apop-
tosis was demonstrated by Western blot analysis of cas-
pase-3 activation. The caspase-3 cleavage induced by Jo2
in MLEC was reduced to control values by co-treatment
with CO, whereas inclusion of PD 98059 abolished this
effect (Figure 6B). These experiments imply a cytopro-
tective role for the ERK1/2 pathway against activation of
the extrinsic apoptotic pathway, which is required for
CO-dependent therapeutic effects (Figure 7).
Discussion
The antiapoptotic potential of CO was first demon-
strated in cell culture studies using fibroblasts or
endothelial cells. Both the exogenous administration of
Figure 2 CO inhibited Jo2-dependent caspase-8 and Bax activation. MLEC cultures were pretreated in the absence or presence of CO (250
ppm) for 2 h prior to the addition of antibody Jo2 (200 ng/ml) for the indicated times. The total lysates were subjected to immunopreciptiation
(IP) with anti-Fas, followed by immunoblotting (IB) to detect caspase-8. Total Fas served as the standard. The control lane (c) represents cell
lysate taken immediately after Jo2 addtion (A). Lysates were subjected to Western blot analysis to detect caspase-8 (B). MLEC cultures were
pretreated in the absence or presence of CO (250 ppm) for 2 h prior to the addition of antibody Jo2 (200 ng/ml) for the indicated times. Lysates
were subjected to immunoprecipitation with antibody 6A7 that specifically recognizes the activated form of Bax, followed by immunoblotting
with anti-Bax. Total Bax served as the standard (C). Westerns are representative of three independent experiments.
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ppm) for 2 h prior to the addition of antibody Jo2 (200 ng/ml) for the indicated times. The total lysates were subjected to Western blot analysis
to detect FLIP (A), or to immunoprecipitation (IP) with anti-Fas followed by immunoblotting (IB) to detect FLIP. b-Actin (A) or Total Fas (B) served
as the standard. Westerns are representative of three independent experiments.
Figure 4 CO inhibited FADD phosphorylation via blockage of JNK signaling. MLEC cultures were pretreated in the absence or presence of
CO (250 ppm) for 2 h prior to the addition of antibody Jo2 (200 ng/ml) for the indicated times. The total lysates were subjected to Western
blot analysis to detect phosphorylated and total FADD (A), or to immunoprecipitation (IP) with anti-Fas followed by immunoblotting to detect
phospho-FADD (B). Lysates were subjected to immunoblotting to detect phospho- and total JNK. (C). MLEC cultures were treated with antibody
Jo2 (200 ng/ml) for the indicated times, in the absence or presence of JNK inhibitor (20 μM). The total lysates were subjected to
immunoprecipitation with anti-Fas followed by immunoblotting to detect phospho-FADD (D). Total FADD (A, B, D) or total JNK (C) served as the
standards. Westerns are representative of three independent experiments.
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induced apoptosis in murine fibroblasts [36]. In the
endothelial cell model, the inhibitory effect of CO on
TNFa-induced apoptosis could be abolished with the
selective chemical inhibitor, SB203580, or a p38 MAPK
dominant negative mutant, implying a critical role for
the p38 MAPK pathway [25]. Furthermore, HO-1 or
CO co-operated with NF-B-dependent anti-apoptotic
genes (c-IAP2 and A1) to protect against TNFa-
mediated endothelial cell apoptosis [39]. Exogenous CO
inhibited anoxia/reoxygenation-induced apoptosis in
pulmonary artery endothelial cells. This effect was asso-
ciated with the activation of MKK3 and p38a MAPK,
and with inhibition of Fas and FasL expression [27,30].
We have recently demonstrated that CO inhibited
hyperoxia-induced endothelial cell apoptosis by downre-
gulating ROS production, and DISC formation in MLEC
[37]. In Jurkatt T cells induced to apoptosis by FasL sti-
mulation, CO promoted, rather than inhibited FasL-
dependent apoptosis, by inhibiting ERK1/2 activation
[40].
The Fas-dependent apoptotic pathway has been impli-
cated in several models of lung or vascular injury,
including acute lung injury and I/R injury [41-43]. In
the current study, we treated MLEC with activating
anti-Fas antibody (Jo2) as a model of Fas-dependent vas-
cular cell apoptosis. Fas is a prototype death receptor
characterized by the presence of an 80 amino acid death
domain in its cytoplasmic tail. This domain is essential
for the recruitment of a number of signaling compo-
nents upon stimulation by either activating anti-Fas
antibodies or cognate FasL that initiate apoptosis. The
DISC consists of an adaptor protein (such as FADD)
and initiator caspases (such as caspase-8) and is essen-
tial for induction of apoptosis [9,10]. A number of pro-
teins have been reported to regulate formation or
activity of the DISC [10].
The adaptor protein FADD is essential for apoptosis
induced by death receptors, mediating aggregation and
autocatalytic activation of caspase-8. FADD has been
shown to undergo phosphorylation at Ser 194 at the
G2/M transition of the cell cycle [44]. When cells are
Figure 5 CO activated ERK and NF-B signaling. MLEC cultures were pretreated in the absence or presence of CO (250 ppm) for 2 h prior to
the addition of antibody Jo2 (200 ng/ml) for the indicated times. The total lysates were subjected to Western blot to detect ERK or NF-B p65
phosphorylation. Total p65 served as the standard. Westerns are representative of three independent experiments.
Figure 6 CO-dependent cytoprotection requires ERK1/2 pathway. MLEC cultures were pretreated with room air (RA) or CO (250 ppm) for 2
h prior to the addition of antibody Jo2 (200 ng/ml). Additionally, PD 98059 (25 μM) or vehicle (DMSO) was added to the cultures for 30 min
prior to Jo2 addition. Cells were then incubated an additional 24 hours in the absence or presence of CO. 200 μl of supernatant medium was
removed for LDH assays as described in Methods (A). The data represent triplicate (n = 3) determinations. Comparisons between the treatment
groups were performed using Student’s T-test (*P < 0.05). The total lysates were subjected to Western blot to detect caspase-3. b-actin served as
the standard (B).
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either undergo cell death by apoptosis or necrosis or
overcome the G2-M block and continue in the division
cycle, often toward a post-mitotic cell death [45,46].
FADD phosphorylation plays a role in the regulation of
cell growth and proliferation [44,47], and also in cellular
sensitivity to apoptosis induced by anticancer drugs [48].
Currently, it remains unclear whether FADD phosphory-
lation is necessary for the assembly and activity of the
DISC [11]. Our data suggest that FADD phosphorylation
and its accumulation in the DISC is necessary for Jo2-
induced apoptosis in MLEC. The kinase(s) regulating
FADD phosphorylation remain unidentified [47]. In
human prostate cancer cell lines, c-Jun NH2-terminal
kinase (JNK), a member of the mitogen-activated pro-
tein kinase (MAPK) family, was associated with FADD
phosphorylation [48]. Our results clearly show that CO
inhibited the phosphorylation of FADD and also inhib-
ited the activation of JNK during Jo2 stimulation. We
also find that CO inhibited the apparent phosphoryla-
tion of FADD in association with Fas. It remains unclear
if the phosphorylation of FADD in this context was a
prerequisite for DISC formation or occurred in the con-
text of a pre-assembled DISC. Previous studies have
suggested that the phosphorylation of FADD at Ser-194
is important in the regulation of the non-apoptotic roles
of FADD in regulating cell proliferation and cell cycle
progression [49,50]. Nevertheless, in MLEC stimulated
with Jo2 we show that the JNK inhibitor JNKi-II inter-
fered with the detection of phospho-FADD in associa-
tion with Fas in the DISC. Consistent with our
observations, JNK activation has been previously impli-
cated in the stimulation of Fas-dependent apoptosis by
vanadate. In this study, JNK activation was shown to be
required for Fas/FADD association [51]. Holmstrom et
al., using the MEK1 inhibitor, have shown that ERK1/2
MAPK pathways can inhibit extrinsic apoptosis at the
level of caspase-8 activation but do not inhibit Fas traf-
ficking or DISC assembly in T cells [52]. While we pro-
pose here that CO inhibited FADD phosphorylation and
DISC assembly in part through downregulation of JNK,
we cannot exclude the possibility that CO also downre-
gulated other kinases involved in FADD phosphoryla-
tion. We also cannot exclude the possibility that the
effects of CO specifically on JNK phosphorylation are
relevant to the activation of the non-apoptotic functions
of FADD, and/or other downstream cellular targets.
The results of our study also suggest the CO inhibited
extrinsic apoptosis at the level of caspase-8 processing
through FLIP activation. FLIP, an endogenous caspase-8
inhibitor, can block Fas-mediated apoptosis through
association with the DISC [53]. Increased levels of FLIP
Figure 7 Proposed pathways of the antiapoptotic effects of CO in Jo2-dependent apoptosis.
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FLIPL,F L I P S,F L I P R can be recruited to the DISC but
they function differently: FLIPS/R prevent the initial clea-
vage step of caspase-8 activation between the p20 and
the p10 subunit of the caspase homology domain;
whereas FLIPL inhibits the final cleavage between the
pro-domain and the p20 subunit of the p43/41 inter-
mediate [14]. Recent studies show that PKCa/b-depen-
dent phosphorylation regulates the ubiquitination of all
c-FLIP proteins, whereas selectively prolongs the stabi-
lity of the short isoforms [16]. CO upregulated FLIPL
expression and increased the association of FLIPL with
the DISC. Currently, we do not understand how CO
upregulates FLIP expression in MLEC. We report that
simultaneous application of CO during Fas-stimulation
promoted the upregulation of ERK1/2 and NF-Bs i g -
naling pathways in MLEC, both of which have been
implicated in FLIP regulation in other cell types [54-56].
The ERK1/2 pathway was at least in part involved in
CO-dependent cytoprotection against Jo2-induced toxi-
city. Chemical inhibition of ERK1/2 reversed the ability
of CO to downregulate Jo2-induced caspase-3 activation.
No direct evidence has been found to date that Fas-
activating antibody can activate the intrinsic (Bax/mito-
chondria) apoptotic pathway. Injection of Jo2 antibody
into survivin
+/- and survivin
+/+ mice showed that survi-
vin
+/- mice appeared normal, but liver lysates revealed a
low-level activation of caspases, with accumulation of
Bax, indicating a pro-apoptotic state [57]. Here, we
found that Jo2 activated Bax in MLEC. It is possible
that CO inhibits Bax activation through the upregulation
of FLIP, which blocks the extrinsic apoptotic pathway at
the level of caspase-8 activation. We have previously
shown that the vector-driven overexpression of FLIP
inhibited Bax activation in MLEC during hyperoxic or
hypoxia/reoxygenation stress [18,19].
Conclusions
In summary, exogenous CO, when applied at low con-
centration, provides protection against Fas-activating
antibody (Jo2)-induced apoptosis in MLEC by inhibit-
ing Fas/caspase-8 and subsequently, Bax signaling
pathways. FADD phosphorylation is important for
DISC formation induced by Jo2. CO inhibits FADD
phosphorylation and association of phospho-FADD
with Fas. Although CO delayed JNK activation, the
relative importance of JNK in regulating the Fas-
dependent pathway remains unclear. CO increases the
level of FLIP protein expression as well as its assimila-
tion in the DISC, which inhibits the cleavage of cas-
pase-8 (Figure 7). These results, taken together
indicate that CO can protect against Fas-activating
antibody-induced apoptosis by inhibiting both extrinsic
(Fas/caspase-8)-dependent and intrinsic (Bax)-
dependent apoptotic signaling pathways. The protec-
tion afforded by CO against activation of executioner
caspase-3 was dependent on ERK1/2 pathway activa-
tion. Strategies to inhibit extrinsic apoptosis may pro-
vide therapeutic options in diseases where Fas-
dependent apoptosis has been implicated in
pathogenesis.
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